Table 1.
Baseline characteristics of patients from the entire study population
| Characteristics | Patients |
|---|---|
| Age (years) | 71.4 (16–88) |
| Sex (female/male) | 141 (53.6%)/122 (46.4%) |
| HCV genotype (1b/2a or 2b) | 198/65 |
| HCC history (absent/present) | 233/30 |
| Body mass index (kg/m2) | 22.6 (15.0–32.9) |
| Serum albumin (g/dL) | 4.0 (2.2–4.9) |
| Total bilirubin (mg/dL) | 0.74 (0.3–2.6) |
| Alanine aminotransferase (IU/L) | 34.0 (10–299) |
| Aspartate aminotransferase (IU/L) | 38.7 (16–224) |
| Gamma‐glutamyl transpeptidase (IU/L) | 31.2 (8–521) |
| Platelet count (×103/μL) | 149 (14–351) |
| α‐Fetoprotein (ng/mL) | 4.5 (0.9–172.3) |
| Liver stiffness (m/s) | 1.41 (0.67–4.35) |
| Antiviral regimens | |
| Daclatasvir + asunaprevir | 67 (25.5%) |
| Ledipasvir/sofosbuvir | 129 (49.1%) |
| Ombitasvir paritaprevir/ritonavir | 2 (0.7%) |
| Sofosbuvir + ribavirin | 65 (24.7%) |
HCC, hepatocellular carcinoma; HCV, hepatitis C virus.